Cargando…

The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins

The long term side effects of any newly introduced drug is a subject of intense research, and often raging controversies. One such example is the dipeptidyl peptidase-IV (DPP4) inhibitor used for treating type 2 diabetes, which is inconclusively implicated in increased susceptibility to acute pancre...

Descripción completa

Detalles Bibliográficos
Autores principales: Chakraborty, Sandeep, Rendón-Ramírez, Adela, Ásgeirsson, Bjarni, Dutta, Mouparna, Ghosh, Anindya S., Oda, Masataka, Venkatramani, Ravindra, Rao, Basuthkar J., Dandekar, Abhaya M., Goñi, Félix M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000Research 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309170/
https://www.ncbi.nlm.nih.gov/pubmed/25671081
http://dx.doi.org/10.12688/f1000research.2-286.v3
_version_ 1782354648089231360
author Chakraborty, Sandeep
Rendón-Ramírez, Adela
Ásgeirsson, Bjarni
Dutta, Mouparna
Ghosh, Anindya S.
Oda, Masataka
Venkatramani, Ravindra
Rao, Basuthkar J.
Dandekar, Abhaya M.
Goñi, Félix M.
author_facet Chakraborty, Sandeep
Rendón-Ramírez, Adela
Ásgeirsson, Bjarni
Dutta, Mouparna
Ghosh, Anindya S.
Oda, Masataka
Venkatramani, Ravindra
Rao, Basuthkar J.
Dandekar, Abhaya M.
Goñi, Félix M.
author_sort Chakraborty, Sandeep
collection PubMed
description The long term side effects of any newly introduced drug is a subject of intense research, and often raging controversies. One such example is the dipeptidyl peptidase-IV (DPP4) inhibitor used for treating type 2 diabetes, which is inconclusively implicated in increased susceptibility to acute pancreatitis. Previously, based on a computational analysis of the spatial and electrostatic properties of active site residues, we have demonstrated that phosphoinositide-specific phospholipase C (PI-PLC) from Bacillus cereus is a prolyl peptidase using in vivo experiments. In the current work, we first report the inhibition of the native activity of PI-PLC by two DPP4 inhibitors - vildagliptin (LAF-237) and K-579. While vildagliptin inhibited PI-PLC at micromolar concentrations, K-579 was a potent inhibitor even at nanomolar concentrations. Subsequently, we queried a comprehensive, non-redundant set of 5000 human proteins (50% similarity cutoff) with known structures using serine protease (SPASE) motifs derived from trypsin and DPP4. A pancreatic lipase and a gastric lipase are among the proteins that are identified as proteins having promiscuous SPASE scaffolds that could interact with DPP4 inhibitors. The presence of such scaffolds in human lipases is expected since they share the same catalytic mechanism with PI-PLC. However our methodology also detects other proteins, often with a completely different enzymatic mechanism, that have significantly congruent domains with the SPASE motifs. The reported elevated levels of serum lipase, although contested, could be rationalized by inhibition of lipases reported here. In an effort to further our understanding of the spatial and electrostatic basis of DPP4 inhibitors, we have also done a comprehensive analysis of all 76 known DPP4 structures liganded to inhibitors till date. Also, the methodology presented here can be easily adopted for other drugs, and provide the first line of filtering in the identification of pathways that might be inadvertently affected due to promiscuous scaffolds in proteins.
format Online
Article
Text
id pubmed-4309170
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher F1000Research
record_format MEDLINE/PubMed
spelling pubmed-43091702015-02-09 The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins Chakraborty, Sandeep Rendón-Ramírez, Adela Ásgeirsson, Bjarni Dutta, Mouparna Ghosh, Anindya S. Oda, Masataka Venkatramani, Ravindra Rao, Basuthkar J. Dandekar, Abhaya M. Goñi, Félix M. F1000Res Research Article The long term side effects of any newly introduced drug is a subject of intense research, and often raging controversies. One such example is the dipeptidyl peptidase-IV (DPP4) inhibitor used for treating type 2 diabetes, which is inconclusively implicated in increased susceptibility to acute pancreatitis. Previously, based on a computational analysis of the spatial and electrostatic properties of active site residues, we have demonstrated that phosphoinositide-specific phospholipase C (PI-PLC) from Bacillus cereus is a prolyl peptidase using in vivo experiments. In the current work, we first report the inhibition of the native activity of PI-PLC by two DPP4 inhibitors - vildagliptin (LAF-237) and K-579. While vildagliptin inhibited PI-PLC at micromolar concentrations, K-579 was a potent inhibitor even at nanomolar concentrations. Subsequently, we queried a comprehensive, non-redundant set of 5000 human proteins (50% similarity cutoff) with known structures using serine protease (SPASE) motifs derived from trypsin and DPP4. A pancreatic lipase and a gastric lipase are among the proteins that are identified as proteins having promiscuous SPASE scaffolds that could interact with DPP4 inhibitors. The presence of such scaffolds in human lipases is expected since they share the same catalytic mechanism with PI-PLC. However our methodology also detects other proteins, often with a completely different enzymatic mechanism, that have significantly congruent domains with the SPASE motifs. The reported elevated levels of serum lipase, although contested, could be rationalized by inhibition of lipases reported here. In an effort to further our understanding of the spatial and electrostatic basis of DPP4 inhibitors, we have also done a comprehensive analysis of all 76 known DPP4 structures liganded to inhibitors till date. Also, the methodology presented here can be easily adopted for other drugs, and provide the first line of filtering in the identification of pathways that might be inadvertently affected due to promiscuous scaffolds in proteins. F1000Research 2015-01-29 /pmc/articles/PMC4309170/ /pubmed/25671081 http://dx.doi.org/10.12688/f1000research.2-286.v3 Text en Copyright: © 2015 Chakraborty S et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://f1000research.com/resources/NIH-publishing-agreement-manuscript-cover-sheet.pdf The author(s) is/are employees of the US NIH and therefore any publishing licenses are also subject to the terms of the NIH Publishing Agreement and Manuscript Cover Sheet. http://creativecommons.org/publicdomain/zero/1.0/ Data associated with the article are available under the terms of the Creative Commons Zero "No rights reserved" data waiver (CC0 1.0 Public domain dedication).
spellingShingle Research Article
Chakraborty, Sandeep
Rendón-Ramírez, Adela
Ásgeirsson, Bjarni
Dutta, Mouparna
Ghosh, Anindya S.
Oda, Masataka
Venkatramani, Ravindra
Rao, Basuthkar J.
Dandekar, Abhaya M.
Goñi, Félix M.
The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins
title The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins
title_full The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins
title_fullStr The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins
title_full_unstemmed The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins
title_short The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins
title_sort dipeptidyl peptidase iv inhibitors vildagliptin and k-579 inhibit a phospholipase c: a case of promiscuous scaffolds in proteins
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309170/
https://www.ncbi.nlm.nih.gov/pubmed/25671081
http://dx.doi.org/10.12688/f1000research.2-286.v3
work_keys_str_mv AT chakrabortysandeep thedipeptidylpeptidaseivinhibitorsvildagliptinandk579inhibitaphospholipasecacaseofpromiscuousscaffoldsinproteins
AT rendonramirezadela thedipeptidylpeptidaseivinhibitorsvildagliptinandk579inhibitaphospholipasecacaseofpromiscuousscaffoldsinproteins
AT asgeirssonbjarni thedipeptidylpeptidaseivinhibitorsvildagliptinandk579inhibitaphospholipasecacaseofpromiscuousscaffoldsinproteins
AT duttamouparna thedipeptidylpeptidaseivinhibitorsvildagliptinandk579inhibitaphospholipasecacaseofpromiscuousscaffoldsinproteins
AT ghoshanindyas thedipeptidylpeptidaseivinhibitorsvildagliptinandk579inhibitaphospholipasecacaseofpromiscuousscaffoldsinproteins
AT odamasataka thedipeptidylpeptidaseivinhibitorsvildagliptinandk579inhibitaphospholipasecacaseofpromiscuousscaffoldsinproteins
AT venkatramaniravindra thedipeptidylpeptidaseivinhibitorsvildagliptinandk579inhibitaphospholipasecacaseofpromiscuousscaffoldsinproteins
AT raobasuthkarj thedipeptidylpeptidaseivinhibitorsvildagliptinandk579inhibitaphospholipasecacaseofpromiscuousscaffoldsinproteins
AT dandekarabhayam thedipeptidylpeptidaseivinhibitorsvildagliptinandk579inhibitaphospholipasecacaseofpromiscuousscaffoldsinproteins
AT gonifelixm thedipeptidylpeptidaseivinhibitorsvildagliptinandk579inhibitaphospholipasecacaseofpromiscuousscaffoldsinproteins
AT chakrabortysandeep dipeptidylpeptidaseivinhibitorsvildagliptinandk579inhibitaphospholipasecacaseofpromiscuousscaffoldsinproteins
AT rendonramirezadela dipeptidylpeptidaseivinhibitorsvildagliptinandk579inhibitaphospholipasecacaseofpromiscuousscaffoldsinproteins
AT asgeirssonbjarni dipeptidylpeptidaseivinhibitorsvildagliptinandk579inhibitaphospholipasecacaseofpromiscuousscaffoldsinproteins
AT duttamouparna dipeptidylpeptidaseivinhibitorsvildagliptinandk579inhibitaphospholipasecacaseofpromiscuousscaffoldsinproteins
AT ghoshanindyas dipeptidylpeptidaseivinhibitorsvildagliptinandk579inhibitaphospholipasecacaseofpromiscuousscaffoldsinproteins
AT odamasataka dipeptidylpeptidaseivinhibitorsvildagliptinandk579inhibitaphospholipasecacaseofpromiscuousscaffoldsinproteins
AT venkatramaniravindra dipeptidylpeptidaseivinhibitorsvildagliptinandk579inhibitaphospholipasecacaseofpromiscuousscaffoldsinproteins
AT raobasuthkarj dipeptidylpeptidaseivinhibitorsvildagliptinandk579inhibitaphospholipasecacaseofpromiscuousscaffoldsinproteins
AT dandekarabhayam dipeptidylpeptidaseivinhibitorsvildagliptinandk579inhibitaphospholipasecacaseofpromiscuousscaffoldsinproteins
AT gonifelixm dipeptidylpeptidaseivinhibitorsvildagliptinandk579inhibitaphospholipasecacaseofpromiscuousscaffoldsinproteins